Article

Lifelong follow-up essential in testis Ca patients

Orlando, FL-A study by researchers from Memorial Sloan-Kettering Cancer Center in New York has given added strength to the recommendation that patients who develop unilateral testicular germ cell tumors should be followed carefully over their lifetimes. The interval between development of a first and second tumor can be 20 or more years, according to their retrospective, 50-year review.

Related Videos
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
1 expert is featured in this series.
Key Limitations of MAIC Analyses
1 expert is featured in this series.
Matching-Adjusted Indirect Comparisons in mHSPC
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Operationalizing TAR-200 and Other Delivery Systems in Practice
Operationalizing TAR-200 and Other Delivery Systems in Practice
Unmet Needs in NMIBC
Unmet Needs in NMIBC
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Anna Myers, CNP, answers a question during a Zoom video interview
Anna Myers, CNP, discusses her approach to preventing UTIs
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Related Content
“Go big or go small”: Current and emerging tools in kidney stone management
April 11th 2025

“Go big or go small”: Current and emerging tools in kidney stone management

Brian R. Stork, MD Hannah Clarke
“The technology in the field of stone management is exciting, and I think it offers patients a lot more options than what they've had in the past,” says Brian Stork, MD.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA clears stapler for use with da Vinci SP surgical system
April 10th 2025

FDA clears stapler for use with da Vinci SP surgical system

Hannah Clarke
This approval marks the first clearance of a stapler designed for single-port robotic surgery in the US.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Label change for testosterone: Implications for urologists, prescribers, and patients
April 9th 2025

Label change for testosterone: Implications for urologists, prescribers, and patients

Hannah Clarke
In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has important implications for urologists and the patients they treat.
Gene therapy shows encouraging efficacy for overactive bladder
April 8th 2025

Gene therapy shows encouraging efficacy for overactive bladder

Hannah Clarke
At week 12, patients in the URO-902 cohorts demonstrated significantly greater improvements in daily microuritions vs placebo.
© 2025 MJH Life Sciences

All rights reserved.